Plethora Solutions Holdings Plc Regulatory News (PLE)

6 January 2012

Plethora Solutions Holdings plc

("Plethora" or "the Company")

Board Appointment

The Company announces that James (Jim) Mellon has been appointed as a Non-Executive Director with immediate effect.

Jim Mellon, based in the Isle of Man, is a renowned fund manager. He began his career with GT Management in the US and in Hong Kong and later became the co-founder and managing director of Thornton Management (Asia) Limited, based in Hong Kong. He is co-founder of Regent Pacific Group and Charlemagne Capital Limited. He is currently chairman of Manx Financial Group Plc, Speymill Plc and Rivington Street Holdings plc, co-chairman of Regent Pacific Group Ltd and West African Minerals Corporation (formerly Emerging Metals Limited), a director of Charlemagne Capital Limited, Webis Holdings plc, Polo Resources Limited, Burnbrae Group Limited and various other investment companies. Mr Mellon holds a Master's Degree in Philosophy, Politics and Economics from Oxford University.

Mr. Mellon has an indirect beneficial interest in 20,000,000 ordinary shares of the Company, representing approximately 10% of the issued share capital.

The Company also announces that Ronald Openshaw has been appointed as Chief Executive on a permanent basis. It was announced earlier this year that following the departure of the previous CEO due to illness that Mr Openshaw would serve in the role of interim CEO & CFO. Mr Openshaw will continue to fulfill the role of CFO for the foreseeable future.

Bill Robinson, Chairman, Plethora said:

 "We are delighted that Jim has agreed to join the board as a non-executive director. His support during the last financing round was pivotal to its success and we look forward to his input at the board with his considerable experience as a global investor."

-Ends-

Enquiries:

Additional information

Save as set out below, there are no further details in relation to the above appointment which require disclosure under paragraph (g) of Schedule 2 to the AIM Rules.

The Directorships and past Directorships of Jim Mellon, aged 54, are listed below:

Further disclosures:

Mr James Mellon is also a Non-Executive Co-Chairman of Regent Pacific Group Ltd, a company listed on the Hong Kong Stock Exchange. The Company has been informed by Mr Mellon that there is an arrest warrant in his name which was originally issued by the South Korean prosecutor's office on 19 December 2000 and subsequently reissued on 14 January 2004. The warrant was due to remain valid and effective until 12 March 2010. The arrest warrant pertains to Mr Mellon's alleged involvement in a conspiracy with Seung-Hyun Jin (''Mr Jin'') and Chang-Kon Koh to manipulate the share price of Regent Securities Co., Ltd ("Regent") and a failure to make adequate investigations in connection with the provision of certain loans by one of Regent's subsidiaries to Mr Jin. Mr Mellon has informed the Company that he denies these allegations which are without substance.

On 3 January 2008, Bigsave Holdings plc, a company of which Jim Mellon was a director, entered into a voluntary liquidation. There were no unsatisfied creditors.

On 8 April 2003, Regent Pacific Fund, a company of which Jim Mellon was a director, entered into a voluntary liquidation. There were no unsatisfied creditors.

On 9 December 2005 Undervalued Assets Fund - Series One, a company of which Jim Mellon was a director, entered into a voluntary liquidation. There were no unsatisfied creditors.

Asian Opportunity Fund 1998 - Series I commenced voluntary liquidation on 5 February 2008 pursuant to its Articles and Association. Jim Mellon was a director within the 12 month periods preceding such date. There were no unsatisfied creditors.

Jim Mellon was also previously a director of Regent Global Fund and Undervalued Assets Greater China Fund Series III, both of which went into voluntary liquidation. These two funds were liquidated with the consent of shareholders as the directors recommended that due to a decline in the size of the funds, they were uneconomic. There were no unsatisfied creditors.

About Plethora:

Plethora is focussed on the development and marketing of products for the treatment of urological disorders. The Company isfocussed on: (i) driving the development of its speciality sales and marketing business, The Urology Company; and (ii) seeking to increase the value of its development assetsthe most advanced of which is PSD502 for the treatment of premature ejaculation.

Plethora's subsidiary, The Urology Company Limited, established in 2009, markets and distributes a range of branded and generic pharmaceutical products, pharmaceutical specials, medical devices and nutritional supplements for the treatment of urology, andrology and obstetric conditions. Its products fall into two categories (i) Professional - where a physician, nurse or other healthcare professional makes a prescribing decision and include Striant® SR, Urolieve®, Hyalofemme® and Dianatal®; and (ii) Consumer - where the consumer/patient makes a buying decision and include Hyalofemme®, Multi-Gyn®, Multi-Mam® and hI-Cran®.

The Company is headquartered in the UK and is listed on the London Stock Exchange (AIM: PLE.L). Further information is available at www.plethorasolutions.co.uk and www.theurologyco.com